<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03345160</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00150453</org_study_id>
    <nct_id>NCT03345160</nct_id>
  </id_info>
  <brief_title>Peanut Oral Immunotherapy in Children: IMPACT Follow Up Study</brief_title>
  <official_title>Open Label Peanut Oral Immunotherapy in Children: IMPACT Follow Up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This application is being submitted as a follow-up to Protocol &quot;Oral Immunotherapy for&#xD;
      Induction of Tolerance in Peanut Allergic Children-The IMPACT Study.&quot; The IMPACT study was a&#xD;
      double-blind, placebo-controlled study of peanut oral immunotherapy in children 12-48 months&#xD;
      of age. As part this protocol, all participants who received placebo treatment were promised&#xD;
      the opportunity to receive open label treatment at the conclusion of the double-blind phase&#xD;
      and initial follow-up. At the time of submitting that protocol, the investigator did not&#xD;
      specify any detailed protocol for the open label crossover treatment, as this is an evolving&#xD;
      field, but the investigator is now ready to offer this open label treatment as promised.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll up to 20 subjects aged 4-9 years old who were enrolled in the placebo&#xD;
      arm of the IMPACT study.&#xD;
&#xD;
      Once subjects have completed participation in the IMPACT study, subjects will be offered the&#xD;
      option of participating in this open label, peanut oral immunotherapy study.&#xD;
&#xD;
      After the informed consent has been signed, subjects will undergo an initial dose escalation&#xD;
      to peanut protein to establish the starting dose for the build-up phase. The starting dose of&#xD;
      peanut protein for the build-up phase will be the highest tolerated dose during the initial&#xD;
      dose escalation. The subject will return to the study site and the first starting dose of&#xD;
      peanut protein will be given under observation. Subjects will be sent home with doses of&#xD;
      peanut protein to administer at home.&#xD;
&#xD;
      Subject will return every 2 weeks for dose adjustments. Once subjects have tolerated a dose&#xD;
      under observation, subjects will then continue dosing at home with OIT and return to the&#xD;
      research unit every 2 weeks for a 1-step dose escalation to a maximum daily dose of 1000 mg.&#xD;
      Participants who do not reach the 1000mg dose by 40-weeks of build-up phase may enter the&#xD;
      maintenance phase at their highest tolerated dose.&#xD;
&#xD;
      When subjects reach their maximum tolerated dose of either 1000 mg per day, or the maximum&#xD;
      tolerated dose during the 40 weeks of the build-up phase, subjects will enter the maintenance&#xD;
      phase. Subjects will continue daily dosing of peanut protein at the maximum tolerated dose&#xD;
      during the 12-week maintenance phase.&#xD;
&#xD;
      At the end of the maintenance phase, subjects will undergo an open peanut oral food challenge&#xD;
      to a maximum of 4000 mg of peanut protein to determine individualized guidelines for the&#xD;
      introduction of peanut into the subject's diet based on the outcome of the open peanut&#xD;
      challenge The primary objective of this protocol is to provide open label peanut oral&#xD;
      immunotherapy (OIT) for those subjects who received placebo treatment in the IMPACT Study .&#xD;
&#xD;
      Secondary objectives will include:&#xD;
&#xD;
      1. Efficacy of the treatment, as defined by an end of treatment oral peanut challenge.&#xD;
&#xD;
      Safety, as measured by the incidence of adverse events and the proportion of subjects who&#xD;
      discontinue treatment due to adverse events&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 27, 2018</start_date>
  <completion_date type="Actual">October 7, 2020</completion_date>
  <primary_completion_date type="Actual">October 7, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open Label crossover</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-related Adverse Events (AEs)</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Number of participants who reported symptoms which were collected as AEs using CTCAE v4.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of Peanut Protein Tolerated at the End-of-treatment Peanut Challenge</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>This measure assessed the amount of peanut protein [in milligrams (mg)] tolerated by each participant at the end-of-treatment peanut challenge.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Treatment Efficacy</condition>
  <arm_group>
    <arm_group_label>Peanut Flour: Open label peanut OIT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is an open label treatment for subjects who had previously received placebo treatment in a prior peanut OIT study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peanut Flour</intervention_name>
    <description>open label oral immunotherapy</description>
    <arm_group_label>Peanut Flour: Open label peanut OIT</arm_group_label>
    <other_name>Peanut Oral Immunotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients who meet all of the following criteria are eligible for enrollment as study&#xD;
        participants, including participants who:&#xD;
&#xD;
          -  Subjects who were randomized to the placebo arm of protocol NA_00077852 &quot;Oral&#xD;
             Immunotherapy for Induction of Tolerance in Peanut Allergic Children.&quot;&#xD;
&#xD;
          -  Parent guardian must be able to understand and provide informed consent&#xD;
&#xD;
          -  Peanut allergy, as defined by a reaction to a cumulative dose of ≤1000 mg of peanut&#xD;
             protein during the End-of-Treatment food challenge from Protocol NA_00077852 &quot;Oral&#xD;
             Immunotherapy for Induction of Tolerance in Peanut Allergic Children&quot;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who meet any of these criteria are not eligible for enrollment as study&#xD;
        participants, including participants who:&#xD;
&#xD;
          -  Inability or unwillingness of a parent guardian to give written informed consent or&#xD;
             comply with study protocol&#xD;
&#xD;
          -  History of severe anaphylaxis to peanut, defined by severe hypoxia, hypotension,&#xD;
             neurological compromise, confusion, cardiovascular collapse, or loss of consciousness&#xD;
&#xD;
          -  Significant chronic disease (other than asthma, rhinitis, or atopic dermatitis)&#xD;
             requiring therapy; e.g., heart disease or cystic fibrosis which is judged by the&#xD;
             investigator to have potential impact on study outcomes or safety.&#xD;
&#xD;
          -  Severe or poorly controlled atopic dermatitis per investigator's discretion&#xD;
&#xD;
          -  Past or current history of eosinophilic gastrointestinal disease&#xD;
&#xD;
          -  Diagnosis of asthma that meets any of the following criteria:&#xD;
&#xD;
               -  Uncontrolled asthma (as per Global Initiative for Asthma [GINA] latest&#xD;
                  guidelines)&#xD;
&#xD;
               -  History of 2 or more systemic corticosteroid courses or 1 systemic course within&#xD;
                  the 3 previous months prior to visit 1 for treating wheezing&#xD;
&#xD;
               -  Prior intubation/mechanical ventilation for asthma&#xD;
&#xD;
          -  Currently receiving β-blocking agents, angiotensin-converting enzyme inhibitors,&#xD;
             angiotensin-receptor blockers, calcium channel blockers or tricyclic antidepressant&#xD;
             therapy.&#xD;
&#xD;
          -  Current participation in another clinical trial or participation in another clinical&#xD;
             trial in the last 90 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Wood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 6, 2017</study_first_submitted>
  <study_first_submitted_qc>November 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <results_first_submitted>September 29, 2021</results_first_submitted>
  <results_first_submitted_qc>October 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 29, 2021</results_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will not be shared</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 19, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT03345160/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Peanut Flour: Open Label Peanut OIT</title>
          <description>This is an open label treatment for subjects who had previously received placebo treatment in a prior peanut oral immunotherapy (OIT) study&#xD;
Peanut Flour: open label oral immunotherapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Peanut Flour: Open Label Peanut OIT</title>
          <description>This is an open label treatment for subjects who had previously received placebo treatment in a prior peanut OIT study&#xD;
Peanut Flour: open label oral immunotherapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.6" lower_limit="6" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-related Adverse Events (AEs)</title>
        <description>Number of participants who reported symptoms which were collected as AEs using CTCAE v4.0.</description>
        <time_frame>up to 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peanut Flour: Open Label Peanut OIT</title>
            <description>This is an open label treatment for subjects who had previously received placebo treatment in a prior peanut OIT study&#xD;
Peanut Flour: open label oral immunotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-related Adverse Events (AEs)</title>
          <description>Number of participants who reported symptoms which were collected as AEs using CTCAE v4.0.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Peanut Protein Tolerated at the End-of-treatment Peanut Challenge</title>
        <description>This measure assessed the amount of peanut protein [in milligrams (mg)] tolerated by each participant at the end-of-treatment peanut challenge.</description>
        <time_frame>up to 52 weeks</time_frame>
        <population>Data reported for each participant.</population>
        <group_list>
          <group group_id="O1">
            <title>Peanut Flour: Open Label Peanut OIT</title>
            <description>This is an open label treatment for subjects who had previously received placebo treatment in a prior peanut OIT study&#xD;
Peanut Flour: open label oral immunotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Peanut Protein Tolerated at the End-of-treatment Peanut Challenge</title>
          <description>This measure assessed the amount of peanut protein [in milligrams (mg)] tolerated by each participant at the end-of-treatment peanut challenge.</description>
          <population>Data reported for each participant.</population>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participant 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks</time_frame>
      <desc>All 7 subjects reported mild symptoms with at least one IP administration. These reactions were collected and reported as AEs. These allergic reactions were expected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Peanut Flour: Open Label Peanut OIT</title>
          <description>This is an open label treatment for subjects who had previously received placebo treatment in a prior peanut OIT study&#xD;
Peanut Flour: open label oral immunotherapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Otitis Externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting-not associated with dosing</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>GERD-not related to dosing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Mild allergic reaction-Initial Dose Escalation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Mild allergic reaction-Dosing related</sub_title>
                <counts group_id="E1" events="158" subjects_affected="7" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea-not associated with dosing</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Allergic Reaction -not related to dosing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Wrist Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Back pain-related to a fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma Exacerbation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Strept Throat</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema Flare</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rash-not related to dosing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert Wood</name_or_title>
      <organization>Johns Hopkins School of Medicine</organization>
      <phone>410-919-7617</phone>
      <email>RWood@JHMI.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

